At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 401 enrolled
Drug / intervention
AbobotulinumtoxinA dose level 1 or 2 +3 morebiological
Likely dose
AbobotulinumtoxinA dose level 1 or 2 0.05 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
In Brief
A Phase 2 clinical trial evaluating AbobotulinumtoxinA dose level 1 or 2, placebo, and 2 other interventions for Glabellar Frown Lines. Completed, enrolled 401 participants across 10 sites.
Detailed Summary
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionDec 2019
Study CompletionAug 2020
TodayJul 2026
First PostedNov 9, 2018
Enrollment StartNov 26, 2018
Primary CompletionDec 9, 2019
Study CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.6 years ago
Interventions
AbobotulinumtoxinA dose level 1 or 2biological
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
placeboother
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
AbobotulinumtoxinA dose 3biological
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
AbobotulinumtoxinA dose 4biological
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines